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ABSTRACT
Background. The COVID-19 outbreak has resulted in collision
between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted
by deferral, modiﬁcation, and even cessation of therapy. Adaptive
measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during

COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care.
Material and Methods. A total of 125 recommendations were
proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2–3 months, respectively. The
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consensus level for each recommendation was classiﬁed as
“strongly recommended” (SR) if more than 90% of experts
agreed, “recommended” (R) if 75%–90% of experts agreed and
“no consensus” (NC) if fewer than 75% agreed. Sarcoma experts
from 11 countries within the Sarcoma European-Latin American
Network (SELNET) consortium participated, including countries in
the Americas and Europe. The European Society for Medical
Oncology-Magnitude of clinical beneﬁt scale was applied to
systemic-treatment recommendations to support prioritization.
Results. There were 80 SRs, 35 Rs, and 10 NCs among the
125 recommendations issued and completed by 31 multi-

disciplinary sarcoma experts. The consensus was higher
among the 75 higher-priority recommendations (85%, 12%,
and 3% for SR, R, and NC, respectively) than in the 50 lowerpriority recommendations (32%, 52%, and 16% for SR, R, and
NC, respectively).
Conclusion. The consensus on 115 of 125 recommendations
indicates a high-level of convergence among experts. The
SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19
outbreak. The Oncologist 2020;25:e1562–e1573

Implications for Practice: The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization
care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect
critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence
to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Beneﬁt scale
was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level
of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.

INTRODUCTION
Deferral, modiﬁcation, and even cessation of therapy are
hindrances affecting patients with cancer during the current
COVID-19 outbreak. The balance between adapting measures to minimize hospital exposure, following the precautionary principle, and offering a more relaxed diagnostic or
therapeutic management while preserving the patient’s survival options is not easy.
More than 80 reports, often short reports and letters,
have addressed the intersection of cancer and COVID-19
care. Although the risk of morbidity and mortality is almost
always higher in patients with cancer than in patients
infected with COVID-19 (i.e., risk of death for pancreatic
cancer is greater than 90%, whereas for COVID-19infected patients, it is usually lower than 5%) [1], the
truth is that the precautionary principle has prevailed
over cancer care continuation in many cases [2]. Elective
surgeries were largely suspended, in some instances,
because of shortage of ventilators, and thus the operating
theaters became extemporaneous intensive care units.
Some reports have focused on the real impact (direct
and indirect) of the COVID-19 outbreak in patients with
cancer. In some locales where the admissions for SARSCoV-2 far exceeded the hospital capacity, it was to be
expected that cancer care would be compromised in a
variety of ways.
Patients with cancer constitute a large population
with a spectrum of risk with respect to immunosuppression. Cancer immunoediting, which represents the interplay between tumor and immune system, ultimately
leads to changes in immune cells, immune modulators,
cytokines, and molecules expression toward the escape
phase and the development of an immunosuppressive
tumor microenvironment [3]. Both speciﬁc diagnoses
and their treatment with chemotherapy, surgical resection, and newer treatments variably compromise immune
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function and render some patients with cancer more susceptible to infections [4].
As with other infections, the innate and adaptive arms
of the immune system play different key roles in the
COVID-19 infection and evolution. SARS-CoV-2 causes an
overwhelming persistent innate-induced inﬂammation that
can lead to a cytokine storm, cytokine-associated lung
injury, and diffuse organ involvement [5]. Alterations of the
CD4+ and CD8+ T cells subsets have been observed, with
loss of functional diversity in CD4+ T cells and increased
expression of regulatory molecules in CD8+ T cells [6, 7].
Hence, it can be assumed that the systemic immunosuppressive state of patients with cancer might result in an
increased risk of COVID-19 infection and poorer prognosis
for this group of patients.
Epidemiological statistics of the cases in China suggested that patients with cancer were at greater risk than
the general population, data which appear to be borne out
more for hematologic malignancies than solid tumors,
although there still appears to be greater risk even for
patients with solid tumor for fatal outcomes from SARS-CoV-2
[8]. Noteworthy, it has been reported that COVID-19–
related deaths were strongly associated with male sex,
older age, and deprivation; severe asthma; uncontrolled
diabetes; cancer; and several other previous, clinical conditions [9].
Importantly, a recent epidemiological report from the
U.K. based on 800 patients with cancer with COVID-19
infection observed a mortality rate of 28%, with older age,
male gender, and comorbidities, such as cardiovascular disease, signiﬁcant prognostic factors related to higher mortality. Remarkably, chemotherapy or other systemic therapy
administered within 4 weeks of testing positive for COVID19 did not have signiﬁcant effect on mortality from COVID19 disease [10].
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Taken together, rapidly evolving data indicate that oncologic patients, such as patients with sarcoma, constitute a
high-risk group more likely to suffer higher mortality and
morbidities than in the general population if infected by
SARS-CoV-2.
Additionally, during the COVID-19 outbreak, the major
risk for patients with cancer is the inability to receive necessary medical services. Decisions on whether or not to postpone cancer treatment and clinical trials need to be made
on a patient-by-patient basis and according to the inherent
tumor risk in each patient and the prevailing situation,
because delays could lead to tumor progression and, ultimately, poorer outcomes [11]. An article on patients’ perspectives reported that up to 30% of oncologic patients
have had changes in their treatment or follow-up care during the COVID-19 pandemic [12]. Beyond the increased
risks, including requiring mechanical ventilation and death,
that should be prospectively analyzed in oncologic patients
with COVID-19 infection, it is also relevant to take into
account the impact of the precautionary principle that is
implemented in our patients [13]. The latter implies that
patients with cancer have suffered delays or cancellation of
diagnostic tests, surgeries, radiation therapies, or systemic
treatments.
The aim of this article is to build a consensus on prioritization aspects in sarcoma care during the current COVID-19
outbreak or future outbreaks, which could appropriately
balance the precautionary principle while preserving the
highest survival probabilities in sarcoma patients.
This consensus has been developed within the Sarcoma
European-Latin American Network (SELNET). This is a
consortium granted by the European Commission within
the Horizon 2020 Call, within the program H2020-SC1-BHC2018-2020 (better health and care, economic growth, and
sustainable health systems). The aim of the SELNET consortium is to improve clinical outcome in sarcoma care,
through a network of reference centers in sarcoma [14].
These guidelines are intended to add value over and
above other clinical practice guidelines reported for oncologic patients in the context of COVID-19 outbreak. Thus,
our guidance focuses speciﬁcally on patients with sarcoma
and thoroughly provides precise details on prioritization of
125 clinical sarcoma situations, whereas the National Institute for Health and Care Excellence (NICE) offers a general
recommendation for any oncologic patient [15], and the
European Society for Medical Oncology (ESMO) offers a
more general recommendation of prioritization for patients
with sarcoma [16].

MATERIALS AND METHODS
The recommendations have been divided into two scenarios, higher and lower priority, to make them simple and replicable. Higher priority is deﬁned as an undelayable
procedure, because the inherent risk of the tumor, affecting
survival or morbidity, would likely exceed the risk of COVID19 infection if this procedure had not been performed. By
contrast, lower priority is deﬁned as a delayable procedure
(at least 2–3 months), because the inherent risk of the
tumor, affecting survival or morbidity, would be low enough

SELNET Recommendations in Sarcoma During COVID-19
that the patient could minimize or avoid hospital frequentation and, consequently, reduce the risk of infection by
COVID-19. A total of 125 recommendations have been proposed in soft tissue, bone, and visceral sarcomas to thoroughly cover details for diagnosis, surgery, radiation therapy,
systemic treatments, follow-up, and clinical research.
These recommendations were proposed by the SELNET
coordinator team and shared with the ofﬁcial partners of
SELNET network. Associated partners were not involved in
this consensus. Each point derived from multidisciplinary
(MDT) expertise discussion from the SELNET coordination
aimed to be pragmatic, detailed, and patient-oriented for
each recommendation.
Ofﬁcial partners had the competence to give their own
opinion if this was clear enough for them or to give the
opinion of their MDT on certain recommendations.
In this consensus, MDT experts participated from AC
Camargo Cancer Center (Sao Paulo, Brazil), Instituto Alexander
Fleming (Buenos Aires, Argentina), Instituto Nacional de
Enfermedades Neoplasicas (Lima, Peru), Instituto Nacional de
Cancerologia (Mexico DF, Mexico), Hospital Calderon Guardia
(San José, Costa Rica), Centre Leon Berard (Lyon, France),
Istituto Nazionale dei Tumori (Milan, Italy), IRCCS Istituto Ortopedico Rizzoli (Bologna, Italy), Abramson Cancer Center
(Philadelphia, Pennsylvania), University Hospital Lund (Lund,
Sweden), Mannheim University Medical Center (Mannheim,
Germany), MD Anderson Cancer Center (Houston, Texas),
Spanish group for Research on Sarcomas, and University Hospital Virgen del Rocio (Sevilla, Spain). Besides that, a European
patient advocacy group (Sarcoma Patients EuroNet) was also
involved in this consensus, as well as the external scientiﬁc
and ethics committees of SELNET.
Among 31 participating experts in the consensus, there
were 18 oncologists (15 for adults and 3 for pediatrics),
4 orthopedic surgeons, 4 surgical oncologists, 2 radiation
oncologists, 1 pathologist, and 1 radiologist. As SELNET
mainly focuses on adult-type sarcomas, no exclusive pediatric oncologist participated in the consensus. Fourteen Latin
American sarcoma experts participated in the consensus:
nine oncologists, four surgeons, and one radiation therapist. Correlations between Latin American and European
Union (E.U.)-U.S. expert recommendations were evaluated using Pearson’s χ2 test for bivariate options (agreement or disagreement) and Mann-Whitney U test for
multivariate options (strongly agree, agree, disagree, and
strongly disagree).
For each recommendation, every participant chose from
the following options: strongly agree, agree, disagree, and
strongly disagree. The neutral option was not offered to
avoid ambiguity.
Those recommendations with ≥90% of consensus
(at least strongly agree plus agree obtained in ≥90% of participants) were considered as strongly recommended. Those
with ≥75% but <90% were considered as recommended,
and the remaining recommendations were considered as
“no consensus was obtained.” The cutoff of 75% has been
the median threshold to deﬁne consensus in Delphi studies
[17], whereas the demanding 90% cut-off was arbitrarily
chosen to indicate the highest consensus range if at least
this percentage was reached.
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To mitigate the subjectiveness, the ESMO-Magnitude of
Clinical Beneﬁt Scale (MCBS) V1.1 was applied to recommendations involving systemic treatments to support
this prioritization strategy (supplemental online Appendix 1)
[18, 19]. Although MCBS has not been formally evaluated for
sarcoma therapies, MCBS methodology was followed for the
estimation of the beneﬁt obtained with different sarcoma
systemic treatments (supplemental online Appendix 2).

RESULTS
From a total of 31 fulﬁlled questionnaires analyzed, the recommendations were distributed as strongly recommended
(SR) in 80, recommended (R) in 35, and no consensus
(NC) in 10. The consensus was higher among the 75 higherpriority recommendations (85%, 12%, and 3% for SR, R,
and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC,
respectively).
Table 1 describes the consensus level for each recommendation and indicates the MCBS in most contexts of systemic treatments. The statistical distribution for each
recommendation is presented in supplemental online
Appendix 1.
Of note, statistically signiﬁcant differences between
Latin American and E.U.-U.S. expert recommendations
were only detected by Pearson’s χ2 and Mann-Whitney
U test in 3 of 125 recommendations (Table 2). E.U.-U.S.
experts proved to be more conservative for the advice
of adjuvant chemotherapy in high grade chondrosarcoma,
the advice of adjuvant radiotherapy in low-grade, deep
soft-tissue sarcoma (STS) larger than 5 cm, and for the
advice of adjuvant radiotherapy in superﬁcial STS larger
than 5 cm.

DISCUSSION
Because sarcoma multidisciplinary committees are so
critical to patient outcomes [20–27], we emphasize the
message that these meetings should continue, at least in
tele-committee format, in the COVID-19 era. Telecommittees should be scheduled on a regular basis
(e.g., weekly), and the following specialists should participate: pathologists, radiologists, surgeons, radiation oncologists, and medical oncologists.
In this article, a prioritization of diagnostic, care, and
follow-up procedures across different sarcoma contexts has
been reached by consensus among sarcoma experts from
different disciplines and from 11 countries among Latin
American, North America, and Europe. This consensus has
been developed within the SELNET consortium as a guide
to protect cancer care in the complex and heterogeneous
ﬁeld of sarcoma during the COVID-19 outbreak. This consensus is intended to offer precise advice on different clinical sarcoma scenarios that the oncology community could
face, with the aim of prioritizing or postponing different
clinical decisions in patients with sarcoma. The general
oncology community should network with expert centers
from sarcoma suspicion, and these guidelines can be used
to determine which actions can and cannot be postponed
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in the management of patients with sarcoma in the COVID19 era.
Several oncology societies and health care providers
issued recommendations, most often on their websites,
regarding adaptive strategies for emergent standards of
care in patients with cancer during the COVID-19 pandemic
[28]. The Cancer Core Europe, which encompasses seven
cancer centers and oncologic institutes in seven European
countries, published a general consensus on the adaptive
measures to minimize the number of hospital visits and to
prevent anticancer treatment that could induce complications of COVID-19 infections. The methodology for these
recommendations was not deﬁned, however [29].
The NICE issued prioritization guidelines on the use of
systemic and radiation treatments for cancer. This guide
established six prioritization levels, from the ﬁrst for curative treatments offering more than 50% chance of success
and adjuvant or neoadjuvant treatment that adds at least
50% chance of cure compared with surgery or radiation
therapy alone, to the last level, which is deﬁned as a noncurative regimen with a 15%–50% chance of palliation or
temporary tumor control and less than 1 year expected
extension of life [30]. Similarly, a radiotherapy prioritization
guide was issued with ﬁve levels. The general modiﬁcations
are based on postponing or avoiding radiation therapy in
cases of little added value or changing treatment plans to
shorten the number of visits to a health care facility [15].
ESMO issued several guidelines, by tumor type, for prioritizing care into three or four categories. In the case of sarcoma, the low-priority proﬁle is typiﬁed by a stable patient
who can safely have delays in treatment for the duration of
the COVID-19 pandemic. The intermediate proﬁle is exempliﬁed by a patient with a noncritical situation but one in
which delay beyond 6 weeks could impair clinical outcomes
[16]. The Society of Surgical Oncology has joined individual
sarcoma expert opinions and has issued six recommendation points based on prioritizing actions considering several
sarcoma contexts [31].
Certainly, this prioritization does not focus only on individual patient risk but also highlights the community risks
and beneﬁt: the reduction of people in transit and the isolation of patients in general decreases contagion risk in the
community, leaving more resources to treat the impact of
COVID-19 pandemic. However, there are consequences for
other group of patients, such as patients with cancer. In The
Netherlands, a remarkable drop in cancer diagnosis was
noticed from pandemic initiation according to a nationwide
cancer registry [32].
There are three principal approaches to conducting consensus methodology research: the consensus development
panel, the nominal group process, and the Delphi technique
[33]. The latter two require at least two sessions or rounds,
being more complex. The consensus development panel is
the most common approach used in health care research.
This approach consists of organized meetings of experts in
a given ﬁeld and usually requires experts in different disciplines to make a multidisciplinary consensus. Usually, this
approach is supported by the literature evidence, and there
are some face-to-face discussions. In sarcoma oncology,
ESMO guidelines follow this consensus development panel

© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Lower Priority

© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Bone sarcoma: Localized disease
23. Bone lesions likely to be benign without symptoms or complication risks [Recommended, 87%]
Bone sarcoma: Advanced disease
24. Lung micronodules (<1 cm) [Recommended, 77%]
25. Indolent metastatic disease (i.e., adamantinoma, periosteal osteosarcoma) [Recommended, 87%]

GIST or other visceral sarcomas: Localized disease
29. Intramural lesions <1–2 cm in the gastrointestinal tract [Strongly recommended, 90%]
30. Uterine mass predominantly intramural, no recent history of symptoms or signs, more likely to be
myoﬁbromas [Recommended, 87%]
GIST or other visceral sarcomas: Advanced disease
31. Appearance of metastatic spread in the context of indolent GIST (PDGFRA mutant, KIT/PDGFRA wild type)
[Recommended, 81%]

Bone sarcoma: Localized disease
17. Any new tumoral lesion with suspicion of malignancy [Strongly recommended, 100%]
18. Bone tumors without suspicion of malignancy but with risk of fracture [Strongly recommended, 100%]
19. Osteochondromas or GCTB with suspicion of malignant transformation [Strongly recommended, 97%]
20. Any suspicion of local recurrence [Strongly recommended, 100%]
Bone sarcoma: Advanced disease
21. Any new bone tumor with metastatic spread [Strongly recommended, 97%]
22. Any new metastatic recurrence with unexpected behavior for the tumor context [Strongly
recommended, 97%]

GIST or other visceral sarcomas: Localized disease
26. Clinically evident intramural gastrointestinal lesion [Strongly recommended, 97%]
27. Clinical and radiological suspicion of uterine leiomyosarcoma (subserosal mass, with recent symptoms)
[Strongly recommended, 97%]
GIST or other visceral sarcomas: Advanced disease
28. Any appearance of new nodules suspected of metastatic spread (except for micronodules or indolent).
Biopsy of metastatic nodules will not be necessary in the context of consistent natural history
[Recommended, 84%]

Soft-tissue sarcoma: Localized disease
32. High-risk (≥40% risk for death, assessed by Sarculator) localized STS of limbs/trunk wall (after neoadjuvant
treatment if indicated) [Strongly recommended, 100%]
33. Intermediate-risk STS (20%–40% risk for death, assessed by Sarculator) [Strongly recommended, 97%]

(continued)

Soft-tissue sarcoma: Localized disease
40. Low-risk tumors (<20% risk for death) (well-differentiated liposarcoma; atypical liposarcoma; low-risk SFT)
[Recommended, 81%]
41. Local recurrence of low-risk tumor [Recommended, 87%]

Surgery

Soft-tissue sarcoma: Localized disease
12. Lesions not ﬁtting with the points 1 or 2 of the higher priority [Strongly recommended, 97%]
13. Retroperitoneal mass with the appearance of well-differentiated liposarcoma [No consensus, only 74%
agreed]
14. Lesions with appearance of desmoid tumors or oligosymptomatic lesions with appearance of TGCT [No
consensus, 74%]
Soft-tissue sarcoma: Advanced disease
15. Lung micronodules (<1 cm) [Recommended, 81%]
16. Appearance of metastatic spread in the context of indolent tumors (i.e. EMCh, or ASPS) [No consensus,
only 74% agreed]

Soft-tissue sarcoma: Localized disease
6. Deep lesions larger than 3 cm or any tumor larger than 5 cm in limbs or trunk wall with no lipoma aspect
[Strongly recommended, 100%]
7. Any lump that even not ﬁtting with point 1 had experienced a recent fast growth [Strongly
recommended, 97%]
8. Lesions with suspicion of local recurrence [Strongly recommended, 97%]
9. Local neuroﬁbroma or TGCT with suspicion of malignant transformation [Strongly recommended, 97%]
Soft-tissue sarcoma: Advanced disease
10. Any new tumoral lesion in somatic tissues with apparent metastatic spread [Strongly
recommended, 100%]
11. Any new metastatic recurrence with unexpected behavior for the tumor context [Strongly
recommended, 94%]

Diagnostic Process

Soft-tissue, bone, or visceral sarcoma: Localized and advanced disease
4. Cases with diagnostic suspicion of bone lesions likely to be benign; desmoid tumors; lipomas; TGCT
[Strongly recommended, 97%].
5. Indolent tumors for which the committee discussion can be delayed, at physician discretion. (i.e., those in
follow-up with length intervals of 6 mo or longer) [Strongly recommended, 94%]

Multidisciplinary Sarcoma Telecommittees

Soft-tissue, bone, or visceral sarcoma: Localized and advanced disease
1. Every new suspicion of sarcoma (soft tissue, bone, or visceral) diagnosis. The only exceptions being the
cases likely to be well-differentiated liposarcoma or low-risk gastric GIST [Strongly recommended, 97%]
2. Therapeutic plan for patients previously diagnosed with any sarcoma with metastatic life-threatening
lesions; Ewing sarcoma; high-grade recurrent resectable tumors; high-risk localized sarcoma; osteosarcoma;
rhabdomyosarcoma (embryonal, alveolar, and sclerosing) [Strongly recommended, 100%]
3. Therapeutic plan for recurrent or progressing sarcomas [Strongly recommended, 97%]

Higher Priority

Table 1. Prioritizing recommendations classiﬁed by higher and lower priority with consensus results for each recommendation (percentage agreeing with the recommendation)
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GIST or other visceral sarcomas: Localized disease
69. Low-risk or very-low-risk GIST without clinical complications [Recommended, 87%]
70. In the context of indolent GISTs (i.e., PDGFRA mutants or KIT/PDGFRA wild type) consider postponing
surgery based on other relevant factors [Strongly recommended, 100%]
71. Any low-grade visceral sarcoma without relevant
symptoms or other complications
[Recommended, 87%]
GIST and other visceral sarcomas: Advanced disease
72. Nodule within mass as GIST progression that could be postponed or managed with radiofrequency
[Strongly recommended, 97%]
73. Metastatic indolent GIST (even oligometastatic) (i.e. PDGFRA) that could be postponed [Strongly
recommended, 97%]

GIST or other visceral sarcomas: Localized disease
63. Clinically evident GIST (consider neoadjuvant imatinib for gastroesophageal junction or gastric antrum or
duodenal or rectal GIST or any bulky GIST to facilitate surgery) [Strongly recommended, 100%]
64. Symptomatic GIST not suitable for neoadjuvant imatinib (i.e., imatinib intolerant or genotype resistant to
imatinib) [Strongly recommended, 97%]
65. Any other visceral grade 2 or grade 3 sarcomas or symptomatic low-grade [Strongly recommended, 100%]
GIST or other visceral sarcomas: Advanced disease
66. In the context of unique or oligometastatic responding patients for whom extending 3-mo imatinib could
be difﬁcult [Strongly recommended, 90%]
67. Multicentric GIST or with nodal involvement (i.e. KIT/PDGFRA wild type GIST) [Strongly
recommended, 94%]
68. Metastatic lesion causing symptomatic or other serious effect not amenable with imatinib [Strongly
recommended, 97%]

Soft-tissue sarcoma: Localized disease
74. Neoadjuvant chemotherapy for extraskeletal Ewing sarcomaa,b and pediatric-type rhabdomyosarcomac
(embryonal, alveolar, and sclerosing) [Strongly recommended, 97%]

(continued)

Soft-tissue sarcoma: Localized disease
82. Perioperative chemotherapy in localized STS of limbs/trunk wall larger than 5 cm, grade 3, and deep
tumors but with risk of death less than 40% based on Sarculator would be postponed or not
recommended [Strongly recommended, 90%]

Medical Oncology

Bone sarcoma: Localized disease
55. Low-grade osteosarcoma (parosteal and other variants) [Recommended, 84%]
56. Low-grade chondrosarcoma [Strongly recommended, 90.32%]
57. Adamantinoma [Recommended, 87%]
58. GCTB without suspicion of malignant transformation (consider induction with denosumab)
[Recommended, 87%]
59. Any other low-grade bone sarcoma [Recommended, 84%]
Bone sarcoma: Advanced disease
60. Indicated metastasectomy but due to indolent behavior, this can be postponed (i.e., adamantinoma, lowgrade bone tumors) [Strongly recommended, 90%]
61. Metastatic GCTB (denosumab can be a therapeutic option) [Strongly recommended, 90%]
62. Pulmonary micronodules with uncertain malignant nature [Strongly recommended, 90%]

Bone sarcoma: Localized disease
46. High-grade conventional osteosarcoma and skeletal Ewing sarcoma after neoadjuvant chemotherapy
[Strongly recommended, 97%]
47. High-grade conventional chondrosarcoma [Strongly recommended, 100%]
48. Mesenchymal chondrosarcoma (upfront or after neoadjuvant chemotherapy, following MDT decision)
[Strongly recommended, 100%]
49. Other high-grade primary bone tumors [Strongly recommended, 97%]
50. High-grade or intermediate grade in local recurrence [Strongly recommended, 97%]
51. Any surgical complication that would be solved by surgery [Strongly recommended, 100%]
Bone sarcoma: Advanced disease
52. Metastasectomies as part of multimodality treatment in osteosarcoma or Ewing sarcoma [Strongly
recommended, 94%]
53. Oligometastatic chondrosarcoma without evidence of local recurrence [Strongly recommended, 97%]
54. Oligometastatic high-grade bone sarcoma without evidence of local recurrence [Strongly
recommended, 97%]

Lower Priority
42. Retroperitoneal sarcoma (well-differentiated liposarcoma, low-grade SFT, desmoid tumors)
[Recommended, 84%]
Soft-tissue sarcoma: Advanced disease
43. Indicate metastasectomy but due to indolent behavior of STS, this can be postponed (i.e. EMCh, ASPS)
[Recommended, 87%]
44. Synchronous metastatic STS or metachronous metastatic STS with a short relapse interval, where
systemic therapy could be tried ﬁrst [Recommended, 87%]
45. Pulmonary micronodules with uncertain malignant nature [Recommended, 84%]

Higher Priority

34. Any local recurrence of grade 2 or 3 STS of limbs/trunk wall [Strongly recommended, 100%]
35. Local therapy for extraskeletal Ewing sarcoma, or rhabdomyosarcoma (embryonal, alveolar, and
sclerosing) [Strongly recommended, 97%]
36. Any surgical complication entailing risk for the patient [Recommended, 87%]
37. Retroperitoneal sarcoma (dedifferentiated liposarcoma, leiomyosarcoma, other high/intermediate grade
sarcomas) [Strongly recommended, 100%]
Soft-tissue sarcoma: Advanced disease
38. Metastasectomies in oligometastatic patients with an adequate time interval without progression
[Strongly recommended, 94%]
39. Any life-threatening resectable metastatic spread in adequate MDT discussion [Strongly
recommended, 97%]
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GIST and other visceral sarcomas: Localized disease
101. Adjuvant imatinib with <40% of recurrence risk (heat maps) [Recommended, 81%]
GIST and other visceral sarcomas: Advanced disease
102. Metastatic indolent disease (i.e., PDGFRA mutant) [Recommended, 87%]
103. Radiological progression without clinical impact [No consensus, 68%]

GIST and other visceral sarcomas: Localized diseasej
97. Neoadjuvant imatinib in locally advanced GIST with sensitive genotype (to facilitate posterior surgery)
[Strongly recommended, 94%]
98. Neoadjuvant imatinib in gastro-esophageal junction, or gastric antrum or rectal GIST (to minimize
morbidity) with sensitive genotype [Strongly recommended, 100%]
99. Adjuvant imatinib in patients with >40% of recurrence risk (heat maps) [Strongly recommended, 100%]
GIST and other visceral sarcomas: Advanced diseasek
100. TKI for ﬁrst, second, and third line in metastatic disease with imatinib, sunitinib, and regorafenib,
respectively [Strongly recommended, 94%]

Soft-tissue sarcoma: Localized disease
104. Perioperative radiation therapy (preferably postoperative during COVID-19 outbreak) in grade 2–3, >5
cm, and deep STS of limbs/trunk wall [Strongly recommended, 97%]
105. Perioperative radiation therapy (preferably postoperative during COVID-19 outbreak) in >5 cm and
superﬁcial STS of any grade in limbs/trunk wall [Recommended, 77%]
106. Perioperative radiation therapy (preferably postoperative during COVID-19 outbreak) in <5 cm and deep
STS of any grade in limbs/trunk wall [No consensus, only 61% agreed]
107. Radiation therapy in cases of head and neck sarcomas [Strongly recommended, 90%]
108. Radiation therapy in rhabdomyosarcomas (embryonal, alveolar, and sclerosing) and extraskeletal Ewing
sarcoma [Strongly recommended, 100%]
Soft-tissue sarcoma: Advanced disease
109. Any symptomatic metastatic lesion that could be alleviated with radiation therapy, balancing risk/beneﬁt
[Strongly recommended, 97%]

(continued)

Soft-tissue sarcoma: Localized disease
111. Postoperative radiation therapy in low grade, >5 cm, and deep STS of limbs or trunk wall [No
consensus, 71%]
Soft-tissue sarcoma: Advanced disease
112. Radiation therapy for local control of asymptomatic primary tumor in the context of metastatic STS
[Recommended, 84%]

Radiation Oncology

Bone sarcoma: Localized disease
92. Perioperative chemotherapy in high-grade bone sarcoma (i.e. Undifferentiated high-grade pleomorphic
bone sarcoma) [No consensus, only 68% agreed]
93. Perioperative chemotherapy in high-grade chondrosarcoma [Recommended, 81%]
Bone sarcoma: Advanced disease
94. Systemic treatment beyond second line of metastatic disease in osteosarcoma or beyond third line in
Ewing sarcoma [Recommended, 81%]
95. Any chemotherapy line in chondrosarcoma [Recommended, 87%]
96. Imatinib in advanced/recurrent asymptomatic chordoma [Strongly recommended, 94%]

Bone sarcoma: Localized disease
86. Neoadjuvant chemotherapy in osteosarcomaf,g or Ewing skeletal sarcomaa,b
[Strongly recommended, 94%]
87. Neoadjuvant chemotherapy in mesenchymal chondrosarcoma potentially resectable.
[Recommended, 87%]
Bone sarcoma: Advanced disease
88. Upfront chemotherapy in metastatic osteosarcoma or Ewing sarcomab [Strongly recommended, 100%]
89. Chemotherapy in recurrent advanced osteosarcoma not suitable for surgeryh [Strongly
recommended, 100%]
90. Chemotherapy in recurrent advanced Ewing sarcomai [Strongly recommended, 100%]
91. Metastatic undifferentiated high-grade bone sarcoma [Strongly recommended, 94%]

Lower Priority
Soft-tissue sarcoma: Advanced disease
83. Newly diagnosed metastatic disease with micronodules [Recommended, 84%]
84. Indolent STS or slow progressive STS with barely or no symptomatic impact [Strongly
recommended, 90%]
85. Progressive disease beyond second with low probability of clinical beneﬁt [Recommended, 84%]

Higher Priority

75. Perioperative chemotherapy in high-risk STS of limbs/trunk wall (>40% death-risk based on Sarculator) (3
cycles of epirubicin + ifosfamide) in selected patientsd [Strongly recommended, 97%]
76. Potentially resectable localized STS [No consensus, only 74% agreed]
Soft-tissue sarcoma: Advanced diseasee
77. Overtly disease progression [Strongly recommended, 94%]
78. Newly diagnosed metastatic disease (other than doubtful micronodules) [Strongly recommended, 97%]
79. Symptomatic patients in relation to their tumor volume [Strongly recommended, 94%]
80. Patients with already initiated chemotherapy, or other systemic treatment with clinical or radiological
beneﬁt [Strongly recommended, 100%]
81. Potentially resectable advanced STS [Strongly recommended, 90%]
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The beneﬁt from alternating cycles of VDC (vincristine, doxorubicin, cyclophosphamide) and IE (ifosfamide and etoposide) over vincristine, doxorubicin, cyclophosphamide chemotherapy in Ewing sarcoma
[39] shows level A of recommendation when applying the European Society for Medical Oncology (ESMO)-Magnitude of Clinical Beneﬁt Scale (MCBS) V11: Form 1.
b
The beneﬁt from VDC/IE over vincristine, ifosfamide, doxorubicin, etoposide chemotherapy in Ewing sarcoma [40] shows level B of recommendation when applying the ESMO- MCBS V11: Form 1.
c
The beneﬁt from ifosfamide, vincristine, actinomycin D when compared with other regiments with more drugs (IVA + Carbo-etoposide-epirubicin and IVA (ifosfamide, vincristine, actinomycin D) + doxorubicin) in rhabdomyosarcoma [41, 42] shows level B of recommendation when applying the ESMO-MCBS V11: Form 1 (IVA is the recommended option as resulted in less toxicity with the same survival
outcome).
d
The beneﬁt from three cycles of epirubicin and ifosfamide in the perioperative setting in high-risk patients with STS [43–45] shows level A of recommendation when applying the ESMO-MCBS V11: Form 1.
(Advanced disease)
e
The beneﬁt from eribulin in liposarcoma [46] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 2A (beneﬁt in overall survival [OS]). The beneﬁt from eribulin in L-sarcoma (liposarcoma and leiomyosarcoma) [46] shows level 3 of recommendation when applying the ESMO-MCBS V11: Form 2A. The beneﬁt from trabectedin in L-sarcoma (liposarcoma and leiomyosarcoma) [47]
shows level 3 of recommendation when applying the ESMO-MCBS V11: Form 2B. The beneﬁt from trabectedin in translocation-related sarcoma [48] shows level 4 of recommendation when applying the
ESMO-MCBS V11: Form 2A (beneﬁt in OS). The beneﬁt from pazopanib in pretreated STS excluding liposarcoma [49] shows level 3 of recommendation when applying the ESMO-MCBS V11: Form 2B.
The beneﬁt from the combination of gemcitabine and dacarbazine in pretreated STS [50] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 2A (beneﬁt in OS). The beneﬁt from

Consider adapting procedures in agreement with the trial sponsor as relax the interval of clinical visits, to minimize as much as possible hospital frequentation.

Soft-tissue, bone, or visceral sarcoma: localized and advanced disease
125. To new enrollment: therapies for indolent entities (TGCT, GCTB, desmoid tumors) for which the
enrollment can be postponed, phase I trials with substantial number of procedures, serious logistic
difﬁculties due to the pandemic situation, CAR-T cells based trials (it could require intensive care
support), immunomodulation therapies that could exacerbate the inﬂammatory response to SARS-CoV-2
[Strongly recommended, 90%]

Clinical Trials

Soft-tissue, bone, or visceral sarcoma: Localized and advanced disease
123. To new enrollment: therapies likely to improve clinical outcome (drugs with strong preclinical rationale,
drugs showing promising results in previous clinical trials, drugs with robust predictive biomarker,
therapy targeting addictive signaling pathway in some tumors, therapy targeting relevant signaling in
orphan diseases) [Strongly recommended, 97%]
124. To maintain the treatment under trial: patients with clinical or radiological beneﬁt, patients still not
assessed for efﬁcacy without relevant toxicity [Strongly recommended, 100%]

a

Soft-tissue, bone, or visceral sarcoma: Localized and advanced disease
122. The follow-up recommendation for low-intermediate risk of STS, low-grade osteosarcoma, high-risk GIST
under adjuvant imatinib, intermediate-low-risk of localized GIST is to schedule CT scans or chest x-ray (in
some cases): every 5–6 mo for the ﬁrst 5 years; every year after the ﬁfth year [Strongly
recommended, 97%]

Consider, in the appropriate context, to prolong the interval 2–3 mo if the patient is beyond the ﬁrst 3 years of follow-up.
The objective is to minimize patient contact with the hospital during the COVID-19 outbreak. As much as possible, teleconsultations should be used during follow-up.

Soft-tissue, bone, or visceral sarcoma: Localized and advanced disease
121. The follow-up recommendation for high-risk STS, conventional osteosarcoma, Ewing sarcoma,
rhabdomyosarcoma (embryonal, alveolar, or sclerosing), high-risk GIST after completion of adjuvant
imatinib is to schedule CT scans or chest x-ray (in some cases): every 3–4 mo for the ﬁrst 3 years; every 6
mo in fourth or ﬁfth years; every year after the ﬁfth year [Strongly recommended, 97%]

Lower Priority

GIST and other visceral sarcomas: Localized disease
119. Postoperative radiation therapy in breast sarcoma larger than 5 cm or high grade [No consensus, only
65% agreed]
GIST and other visceral sarcomas: Advanced disease
120. Radiation therapy for unresectable breast or uterine sarcoma with metastatic spread [No consensus,
only 74% agreed]

Follow-Up

GIST and other visceral sarcomas: Localized disease
117. Radiation therapy for unresectable breast or uterine sarcoma [Strongly recommended, 97%]
GIST and other visceral sarcomas: Advanced disease
118. Any symptomatic metastatic lesion that could be alleviated with radiation therapy, balancing risk/beneﬁt
[Strongly recommended, 100%]

Bone sarcoma: Localized disease
113. Radiation therapy is skeletal Ewing sarcoma according to CPG [Strongly recommended, 100%]
114. Unresectable osteosarcoma after induction chemotherapy [Strongly recommended, 94%]
115. Deﬁnitive radiation therapy for grade 3 chondrosarcoma [Recommended, 87%]
Bone sarcoma: Advanced disease
116. Any symptomatic metastatic lesion that could be alleviated with radiation therapy, balancing risk/beneﬁt
[Strongly recommended, 97%]

110. Radiation therapy for symptomatic primary tumor in the context of metastasis [Strongly
recommended, 100%]
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the combination of gemcitabine and docetaxel in advanced STS [51] and in advanced leiomyosarcoma [52] shows level 1 of recommendation when applying the ESMO-MCBS V11: Form 2C. The beneﬁt from
high-dose ifosfamide in advanced STS [53] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 3. The beneﬁt from doxorubicin in advanced STS [54] shows level 4 of recommendation when applying the ESMO-Magnitude of Clinical Beneﬁt Scale (MCBS) V11: Form 3.
f
The beneﬁt from adjuvant chemotherapy in resected conventional osteosarcoma [55, 56] shows level A of recommendation when applying the ESMO-MCBS V11: Form 1.
g
The beneﬁt from the addition of Mifamurtide to adjuvant chemotherapy in resected conventional osteosarcoma [57] shows level A of recommendation when applying the ESMO-MCBS V11- Form 1.
h
The beneﬁt from cisplatin in advanced osteosarcoma [58] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form C. The beneﬁt from cisplatin + doxorubicin + ifosfamide in advanced
osteosarcoma [59] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form C. The beneﬁt from ifosfamide-etoposide in advanced osteosarcoma [60] shows level 3 of recommendation
when applying the ESMO-MCBS V11: Form C. The beneﬁt from high-dose ifosfamide in advanced osteosarcoma [61] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form C. The beneﬁt from sorafenib plus everolimus [62] and regorafenib [63] in advanced osteosarcoma shows level 2 of recommendation when applying the ESMO-MCBS V11- Form C.
i
The beneﬁt from gemcitabine and docetaxel in Ewing sarcoma [64, 65] shows level 2 of recommendation when applying the ESMO-MCBS V11: Form C. The beneﬁt from Cyclophosphamide-topotecan cannot
be properly assessed with the currently available evidence. The beneﬁt from high-dose ifosfamide in Ewing sarcoma [66] shows level 3 of recommendation when applying the ESMO-MCBS V11- Form C.
j
The beneﬁt from 3 years of adjuvant imatinib in localized GIST [67] shows level A of recommendation when applying the ESMO-MCBS V11- Form 1.
k
The beneﬁt from imatinib in advanced GIST [68] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 3. The beneﬁt from sunitinib in advanced GIST [69, 70] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 2B and Form 2A, respectively. The beneﬁt from regorafenib in advanced GIST [71] shows level 3 of recommendation when applying the ESMO-MCBS
V11: Form 2B. The beneﬁt from ripretinib in advanced GIST [72] shows level 4 of recommendation when applying the ESMO-MCBS V11: Form 2B and Form 2A, respectively.
Abbreviations: ASPS, alveolar soft part sarcoma; CAR-T, chimeric antigen receptor T-Cell; CT, computed tomography; EMCh extraskeletal myxoid chondrosarcoma; GCTB, giant cell tumor of bone; GIST, gastrointestinal stromal tumor; MCBS, Magnitude of Clinical Beneﬁt Scale; MDT, multidisciplinary; SFT, solitary ﬁbrous tumor; STS, soft-tissue sarcoma; TGCT, tenosynovial giant cell tumor; TKI, tyrosine kinase
inhibitor.
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approach [25, 27, 34]. The consensus we present here
has two main differences in comparison with the consensus development panel. Despite the proposed prioritizing
recommendations based on the published evidence, there
are no comparative studies analyzing, for instance, the
delay of some treatments in patients with sarcoma. In
addition, no formal face-to-face meeting was organized
because of inherent conﬁnement constraints. In contrast,
the fact that all expert participants provided their own
opinion on each recommendation ensures more independence and the quality of the conclusions, avoiding interferences that could arise in a face-to-face discussion.
In contrast, with the aim to minimize the subjectivity
in the recommendation process, the ESMO-MCBS was fulﬁlled, at least for systemic therapies applied in sarcoma.
We tried to adopt the grade 3 or higher and grades A or
B scores, in the systemic treatment, as the cut-off for preserving the use of such treatments in the COVID-19 pandemic era. The ESMO-MCBS v1.1 is a validated scale
measuring the magnitude of clinical beneﬁt and adds
value with just the statistical signiﬁcance focus [18].
Although there is not yet an ESMO-MCBS for sarcoma,
our exercise has followed the rules of the scale and is an
additional support for this consensus.
The fact that 80 of 125 recommendations were
“strongly recommended” and only 10 were “no consensus” indicates a high grade of accord among sarcoma
experts in this consensus on prioritization. The fact that
lower consensus was obtained in the low priority group
might indicate the reticence of sarcoma experts in postponing treatment, even in indolent or low-risk cases.
This consensus has been mainly addressed keeping in
mind Latin-American communities, and thus it has pursued simplicity and concision, taking into consideration
that there are many health care providers in each country. Hence, assigning higher or lower priority to those
undelayable or delayable treatments, respectively, facilitates the decision-making process in patients with sarcoma. Additionally, this SELNET consensus issues
125 recommendations, which indicates a high level of
thoroughness, covering a substantial spectrum of
sarcoma care.
Follow-up recommendations in the context of sarcoma remains largely unstudied [35] and usually are
based on conventions; thus, in high-risk patients, for
example, the imaging tests are performed every 3–4
months for the ﬁrst 3 years, then every 6 months for the
4th and 5th years, and so on, once per year. This strategy
is based on the higher risk of recurrence observed in the
ﬁrst 3 years after treatment for localized disease and the
fact that the asymptomatic recurrence, detected by computed tomography scan for instance, could potentially
have higher curative options. There are some reports
addressing the relevance of smaller size as independent
prognostic relevance, at the time of metastatic disease,
for longer survival [36–38]. Nevertheless, the truth is that
convincing evidence that determined strategy is related
with better survival is lacking, and a lead-time bias can
occur in highly interventionist follow-up.

© 2020 The Authors.
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Table 2. Mann-Whitney U and Pearson’s χ2 test for those recommendations with statistical differences between LATAM
and E.U.-U.S. experts
Pearson’s χ2 test

Mann-Whitney test
Recommendations
Recommendation
no. 93

LATAM, %

E.U.-U.S., %

Strongly agree
Agree
Disagree
Strongly disagree
Recommendation
no. 105
Strongly agree
Agree
Disagree
Strongly disagree
Recommendation
no. 111
Strongly agree
Agree

38
31
31
0

7
64
22
7

Disagree
Strongly disagree

p value
.001

Agree
Disagree
.008

25
38
31
6

64
36
0
0

21
21

6
0

58
0

LATAM, %

E.U.-U.S., %

57
43

100
0

Recommendation
no. 105
Agree
Disagree

.021
41
53

Recommendations
Recommendation
no. 93

p value
.009

.01

100
0

63
37

Recommendation
no. 111

.002

Agree

43

94

Disagree

57

6

Recommendation (R) no. 93 collects agreement as a low priority for adjuvant chemotherapy in high-grade localized chondrosarcoma. R no. 105
collects agreement as a high priority for perioperative radiation therapy in superﬁcial soft-tissue sarcoma (STS) larger than 5 cm, and R no. 114
collects agreement as a lower priority for low-grade, deep STS and larger than 5 cm.
Abbreviations: E.U., European Union; LATAM, Latin-American.

CONCLUSION
This SELNET consensus provides a tool for multidisciplinary
sarcoma committees during the COVID-19 outbreak. The
detail of different recommendations and the distinction
between the two levels of prioritization enables a practical
approach for Latin-American health care providers and sarcoma expert centers.
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